Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease

Por Tampi, Rajesh R, van Dyck, Christopher H
Publicado em 2007

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

Por Nygaard, Haakon B, van Dyck, Christopher H, Strittmatter, Stephen M
Publicado em 2014

Cognitive and psychiatric effects of vitamin B(12) replacement in dementia with low serum B(12) levels: a nursing home study

Por van Dyck, Christopher H., Lyness, Jeffrey M., Rohrbaugh, Robert M., Siegal, Alan P.
Publicado em 2008

α2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals

Por Ramos, Brian P., Stark, David, Verduzco, Luis, van Dyck, Christopher H., Arnsten, Amy F.T.
Publicado em 2006

Clinical Trials: New Opportunities

Por Chapman, Sandra Bond, Cotman, Carl W., Fillit, Howard M., Gallagher, Michela, van Dyck, Christopher H.
Publicado em 2012

Variation at APOE and STH loci and Alzheimer's disease

Por Zuo, Lingjun, van Dyck, Christopher H, Luo, Xingguang, Kranzler, Henry R, Yang, Bao-zhu, Gelernter, Joel
Publicado em 2006

Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress

Por Hains, Avis Brennan, Vu, Mai Anh T., Maciejewski, Paul K., van Dyck, Christopher H., Gottron, Melissa, Arnsten, Amy F. T.
Publicado em 2009

Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials

Por Karlawish, Jason, Kim, Scott Y. H., Knopman, David, van Dyck, Christopher H., James, Bryan D., Bioethics, M., Marson, Daniel
Publicado em 2008

BDNF Variants, Premorbid Educational Attainment, and Disease Characteristics in Alzheimer’s Disease: An Exploratory Study

Por Zdanys, Kristina F., Kleiman, Timothy G., Zhang, Huiping, Ozbay, Fatih, MacAvoy, Martha G., Gelernter, Joel, van Dyck, Christopher H.
Publicado em 2009

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Por Galasko, Douglas, Bell, Joanne, Mancuso, Jessica Y., Kupiec, James W., Sabbagh, Marwan N., van Dyck, Christopher, Thomas, Ronald G., Aisen, Paul S.
Publicado em 2014

Clinically Relevant Doses of Methylphenidate Significantly Occupy the Norepinephrine Transporter in Humans In Vivo

Por Hannestad, Jonas, Gallezot, Jean-Dominique, Planeta-Wilson, Beata, Lin, Shu-Fei, Williams, Wendol A., van Dyck, Christopher H., Malison, Robert T., Carson, Richard E., Ding, Yu-Shin
Publicado em 2010

Brain Derived Neurotrophic Factor Gene (BDNF) Variants and Alzheimer's Disease, Affective Disorders, Posttraumatic Stress Disorder, Schizophrenia and Substance Dependence

Por Zhang, Huiping, Ozbay, Fatih, Lappalainen, Jaakko, Kranzler, Henry R., van Dyck, Christopher H., Charney, Dennis S., Price, Lawrence H., Southwick, Steven, Yang, Bao-Zhu, Rasmussen, Ann, Gelernter, Joel
Publicado em 2006

Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT

Por Mitsis, Effie M., Cosgrove, Kelly P., Staley, Julie K., Bois, Frederic, Frohlich, Erin B., Tamagnan, Gilles D., Estok, Kristina M., Seibyl, John P., van Dyck, Christopher H.
Publicado em 2008

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Por Turner, R. Scott, Thomas, Ronald G., Craft, Suzanne, van Dyck, Christopher H., Mintzer, Jacobo, Reynolds, Brigid A., Brewer, James B., Rissman, Robert A., Raman, Rema, Aisen, Paul S.
Publicado no Neurology (2015)

High Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer’s Disease: A Randomized Controlled Trial

Por Aisen, Paul S., Schneider, Lon S., Sano, Mary, Diaz-Arrastia, Ramon, van Dyck, Christopher H., Weiner, Myron F., Bottiglieri, Teodoro, Jin, Shelia, Stokes, Karen T., Thomas, Ronald G., Thal, Leon J.
Publicado em 2008

Striatal dopamine transporters correlate with simple reaction time in elderly subjects

Por van Dyck, Christopher H., Avery, Robert A., MacAvoy, Martha G., Marek, Kenneth L., Quinlan, Donald M., Baldwin, Ronald M., Seibyl, John P., Innis, Robert B., Arnsten, Amy F. T.
Publicado em 2007

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial

Por Quinn, Joseph F., Raman, Rema, Thomas, Ronald G., Yurko-Mauro, Karin, Nelson, Edward B., Van Dyck, Christopher, Galvin, James E., Emond, Jennifer, Jack, Clifford R., Weiner, Michael, Shinto, Lynne, Aisen, Paul S.
Publicado em 2010

Fyn Inhibition Rescues Established Memory and Synapse Loss in Alzheimer Mice

Por Kaufman, Adam C., Salazar, Santiago V., Haas, Laura T., Yang, Jinhee, Kostylev, Mikhail A., Jeng, Amanda T., Robinson, Sophie A., Gunther, Erik C., van Dyck, Christopher H., Nygaard, Haakon B., Strittmatter, Stephen M.
Publicado no Ann Neurol (2015)

Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study

Por Brumberg, Joachim, Küsters, Sebastian, Al‐Momani, Ehab, Marotta, Giorgio, Cosgrove, Kelly P., van Dyck, Christopher H., Herrmann, Ken, Homola, György A., Pezzoli, Gianni, Buck, Andreas K., Volkmann, Jens, Samnick, Samuel, Isaias, Ioannis U.
Publicado no Ann Clin Transl Neurol (2017)

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Por Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., van Dyck, Christopher H., Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S.
Publicado no Neurology (2017)